ARDELYX, INC. Revenue from Related Parties
ARDELYX, INC. (ARDX) reported Revenue from Related Parties of $2.42 million for the 12-month period ending 2015-12-31, per its 10-K filed 2018-03-14.
Discontinued › Income Statement › Other Income
us-gaap:RevenueFromRelatedParties · last filed 2018-03-14
- ARDELYX, INC. revenue from related parties for the quarter ending 2015-12-31 was $0.00, a 100.00% decline year-over-year.
- ARDELYX, INC. revenue from related parties for the quarter ending 2015-09-30 was $0.00, a 100.00% decline year-over-year.
- ARDELYX, INC. revenue from related parties for the quarter ending 2015-06-30 was $416.00K, a 84.18% decline year-over-year.
- ARDELYX, INC. revenue from related parties for the quarter ending 2015-03-31 was $2.00M, a 62.38% decline year-over-year.
- ARDELYX, INC. revenue from related parties for fiscal 2015 was $2.42M, a 81.74% decline from fiscal 2014.
- ARDELYX, INC. revenue from related parties for fiscal 2014 was $13.23M, a 36.60% decline from fiscal 2013.
- ARDELYX, INC. revenue from related parties for fiscal 2013 was $20.86M, a 836.49% increase from fiscal 2012.
- ARDELYX, INC. revenue from related parties for fiscal 2012 was $2.23M.
| Period end | Revenue from Related Parties 3 month | Revenue from Related Parties 6 month | Revenue from Related Parties 9 month | Revenue from Related Parties 12 month |
|---|---|---|---|---|
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | $0.00 derived: sum of 2 quarters · filed 2018-03-14 | $416.00K derived: sum of 3 quarters · filed 2018-03-14 | $2.42M 10-K · filed 2018-03-14 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $416.00K derived: sum of 2 quarters · filed 2016-11-07 | $2.42M 10-Q · filed 2016-11-07 | $4.87M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-06-30 | $416.00K 10-Q · filed 2016-08-08 | $2.42M 10-Q · filed 2016-08-08 | $4.87M derived: sum of 3 quarters · filed 2017-02-17 | $7.70M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-03-31 | $2.00M 10-Q · filed 2016-05-09 | $4.45M derived: sum of 2 quarters · filed 2017-02-17 | $7.28M derived: sum of 3 quarters · filed 2017-02-17 | $9.91M derived: sum of 4 quarters · filed 2017-02-17 |
| 2014-12-31 | $2.45M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $5.29M derived: sum of 2 quarters · filed 2017-02-17 | $7.92M derived: sum of 3 quarters · filed 2017-02-17 | $13.23M 10-K · filed 2017-02-17 |
| 2014-09-30 | $2.83M 10-Q · filed 2015-11-12 | $5.46M derived: sum of 2 quarters · filed 2015-11-12 | $10.78M 10-Q · filed 2015-11-12 | $17.17M derived: sum of 4 quarters · filed 2016-03-04 |
| 2014-06-30 | $2.63M 10-Q · filed 2015-08-12 | $7.94M 10-Q · filed 2015-08-12 | $14.34M derived: sum of 3 quarters · filed 2016-03-04 | $18.94M derived: sum of 4 quarters · filed 2016-03-04 |
| 2014-03-31 | $5.31M 10-Q · filed 2015-05-12 | $11.71M derived: sum of 2 quarters · filed 2016-03-04 | $16.31M derived: sum of 3 quarters · filed 2016-03-04 | $21.61M derived: sum of 4 quarters · filed 2016-03-04 |
| 2013-12-31 | $6.39M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-04 | $11.00M derived: sum of 2 quarters · filed 2016-03-04 | $16.30M derived: sum of 3 quarters · filed 2016-03-04 | $20.86M 10-K · filed 2016-03-04 |
| 2013-09-30 | $4.60M 10-Q · filed 2014-11-07 | $9.91M derived: sum of 2 quarters · filed 2014-11-07 | $14.47M 10-Q · filed 2014-11-07 | |
| 2013-06-30 | $5.30M 10-Q · filed 2014-08-08 | $9.87M 10-Q · filed 2014-08-08 | ||
| 2012-12-31 | $2.23M 10-K · filed 2015-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |